Jump to content

Napp Pharmaceuticals

From Wikipedia, the free encyclopedia

This is an old revision of this page, as edited by AnomieBOT (talk | contribs) at 08:06, 4 October 2019 (Dating maintenance tags: {{Cn}}). The present address (URL) is a permanent link to this revision, which may differ significantly from the current revision.

Napp Pharmaceuticals Limited is a private pharmaceutical company in Cambridge, United Kingdom, that was founded in 1923,[1] and bought by the Sackler brothers in 1966.[citation needed] Located in the Cambridge Science Park together with the related Napp Research Centre it is a sister company of Purdue Pharma and Mundipharma, all owned by the descendants of Mortimer Sackler and Raymond Sackler.

The company produces an array of pharmaceutical products, many for pain management, among them Oxycodone and its derivatives that have been identified as key drugs in the opioid epidemic.[2][3]

In the early 1970s scientists at Napp developed a delivery system whereby a pill would be continuously delivering a drug over a 12 hour period.[4] This Continus® delivery system was used by Purdue first to introduce MS Continus in 1987 and Oxycontin eight years later.

External links[

References

  1. ^ Glassdoor.com listing
  2. ^ Rebecca L. Haffajee, Michelle M. Mello (December 17, 2017). "Drug Companies' Liability for the Opioid Epidemic". New England Journal of Medicine. doi:10.1056/NEJMp1710756.
  3. ^ David Armstrong (February 21, 2019). "Sackler Embraced Plan to Conceal OxyContin's Strength From Doctors, Sealed Testimony Shows". ProPublica. Retrieved February 27, 2019.
  4. ^ David Crowe (September 8, 2018). "What next for the Sacklers? A pharma dynasty under siege". Financial Times. Retrieved February 24, 2019.